Table 5. Comparison of discriminative performance of biomarkers combined with qSOFA.
| qSOFA | MDW and qSOFA | WBC count and qSOFA | CRP and qSOFA | PCT and qSOFA | qSOFA, WBC count, and MDW | |
|---|---|---|---|---|---|---|
| All patients (n = 549) | ||||||
| AUC (95% CI) | 0.67 (0.62–0.72) † | 0.76 (0.72–0.80)* | 0.69 (0.64–7.34) | 0.77 (0.73–0.81)* | 0.76 (0.72–0.81)* | 0.78 (0.74–0.82)* |
| Immune-competenta (n = 242) | ||||||
| AUC (95% CI) | 0.70 (0.62–0.78) † | 0.70 (0.61–0.79) | 0.68 (0.58–0.77) | 0.74 (0.65–0.82) | 0.70 (0.61–0.79) | 0.71 (0.62–0.80) |
| Immune-compromisedb (n = 307) | ||||||
| AUC (95% CI) | 0.66 (0.59–0.72) † | 0.74 (0.69–0.80) | 0.66 (0.60–0.73) | 0.71 (0.66–0.77) | 0.74 (0.69–0.80) | 0.74 (0.69–0.80) |
MDW, monocyte distribution width; WBC, white blood cell; CRP, C-reactive protein; PCT, procalcitonin; CI, confidence interval; qSOFA, quick Sequential Organ Failure Assessment.
aImmune-competent was defined as patients not immune-compromised.
bImmune-compromised is defined as patients with any malignancy, who were treated with G-CSF, with neutropenia, who underwent organ transplantation, or with acquired immunodeficiency syndrome.
*The AUC is significantly different from that of qSOFA.